Drug Profile
PGL 3
Alternative Names: PGL-3; PGL-3001Latest Information Update: 17 Jun 2015
Price :
$50
*
At a glance
- Originator Ipsen
- Developer PregLem
- Class Infertility therapies; Peptides
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Female infertility
Most Recent Events
- 11 Oct 2010 Phase-II development is ongoing in Switzerland
- 07 Oct 2010 PregLem has been acquired by Gedeon Richter
- 27 Jun 2007 Phase-II clinical trials in Female infertility in Switzerland (unspecified route)